Adicet Bio, Inc. (ACET) Reports Positive SLE/LN Phase 1 Data, Plans Pivotal LN Study Start-Up in Q4 2026

Adicet Bio reported positive safety and efficacy from a Phase 1 study of prula-cel in SLE with or without lupus nephritis, and plans to initiate start-up activities for a single-arm pivotal LN study in Q4 2026 with complete renal response at 12 months as the primary endpoint.Material DetailsContext…